Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus risperidone for frontal brain activation in schizophrenia
NL-OMON31229Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of aripiprazole and risperidone in schizophrenia and Schizophrenia Spectrum Disorders (SSD) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Prefrontal cortex brain activity, Task performance accuracy and 3 more. Started Jan 2008; status: active, not recruiting.
02
Drugs
aripiprazolerisperidone
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON31229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31229.